Novartis to pay up to $2 billion for US biotech firm Excellergy - Reuters

Novartis agreed to acquire Excellergy, a US-based biotech firm, for up to $2 billion in an all-cash deal. The acquisition reflects Novartis's strategy to expand its portfolio in emerging therapeutic areas through targeted M&A of smaller biotech companies. Excellergy's technology or pipeline addresses a specific therapeutic need that aligns with Novartis's development priorities. The deal is expected to close subject to customary closing conditions and regulatory approvals. This move underscores the Swiss pharma giant's continued investment in bolt-on acquisitions to strengthen its competitive position in the biotech space.